Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock remains negative
Q1 FY2026 common stock was $0, compared with $94K a year earlier.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 92K | +12.2% |
| FY2023 | 2023-12-31 | 82K | +17.1% |
| FY2022 | 2022-12-31 | 70K | +1.4% |
| FY2021 | 2021-12-31 | 69K | — |
Common Stock vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's Mar 2026 common stock of $0 is the 10th highest of the 11 companies compared; the peer median is $144K.
- Its year-over-year change of -100.0% is the 10th highest of 11, against a peer median of +1.3%.
- Common stock amounts to 0.0% of total assets for RARE, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.73M | +15.1% | +9.1% | 0.5% | |
| Mar 2026 | $3.15M | +0.4% | +8.2% | 7.7% | |
| Mar 2026 | $1.09M | +2.2% | +11.0% | 0.4% | |
| Mar 2026 | $568K | +15.9% | +45.9% | 0.3% | |
| Jun 2026 | $206K | +4.0% | +8.8% | 0.0% | |
| Jun 2026 | $82K | +5.1% | +3.6% | 0.0% | |
| Mar 2026 | $5K | +0.0% | +26.0% | 0.0% | |
| Mar 2026 | $5K | +0.0% | +7.7% | 0.0% | |
| Mar 2026 | $3K | +0.0% | +14.5% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Sep 2026 | -$10.66B | -5550620.8% | +1.1% | 0.1% | |
| Peer median (excluding RARE) | $144K | +1.3% | +8.9% | 0.1% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 307.58M | 132.94M | 213.58M | 173.73M | 434M |
| Short-term Investments | 432.61M | 614.82M | 363.63M | 436.3M | 259M |
| Net Receivables | 44.43M | 40.45M | 73.39M | 121.8M | 159M |
| Inventory | 16.23M | 26.77M | 33.97M | 45.01M | 52M |
| Other Current Assets | 55.75M | 68.93M | 47.62M | 40.29M | 47M |
| Total Current Assets | 856.6M | 883.9M | 732.18M | 817.12M | 951M |
| Property, Plant & Equipment (Net) | 176.18M | 259.73M | 290.57M | 265.93M | 267M |
| Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44M |
| Intangible Assets | 130.79M | 160.11M | 166.27M | 178.31M | 176M |
| Long-term Investments | 293.86M | 148.97M | 199.9M | 135M | 59M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 20.56M | 48.34M | 57.69M | 62.68M | 35M |
| Total Non-current Assets | 665.79M | 661.55M | 758.83M | 686.33M | 581M |
| Total Assets | 1.52B | 1.55B | 1.49B | 1.5B | 1.53B |
| Account Payables | 17.14M | 43.27M | 42.11M | 38.76M | 31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 81M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.61M | 1.48M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 142.79M | 87.47M | 183M |
| Total Current Liabilities | 181.37M | 261.21M | 280.44M | 344.15M | 384M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.17B |
| Deferred Tax Liabilities | 33.31M | 31.67M | 30.06M | 30.06M | 30M |
| Deferred Revenue (Non-current) | 1.47M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 352.79M | 880.26M | 874.53M | 836.91M | (4M) |
| Total Non-current Liabilities | 418.47M | 931.74M | 935.16M | 897.01M | 1.22B |
| Total Liabilities | 599.84M | 1.19B | 1.22B | 1.24B | 1.61B |
| Common Stock | 69K | 70K | 82K | 92K | 0 |
| Retained Earnings | (2.07B) | (2.78B) | (3.39B) | (3.96B) | (4.53B) |
| Accumulated OCI | (1.4M) | (6.57M) | 647K | (643K) | 1M |
| Other Stockholders Equity | 0 | 0 | 432K | 3.59M | 8M |
| Minority Interest | 0 | 0 | 0 | 7M | 7M |
| Total Equity | 922.56M | 352.49M | 275.41M | 262.3M | (73M) |
| Total Debt | 41.97M | 31.59M | 43.17M | 40.34M | 1.28B |
| Net Debt | (265.61M) | (101.35M) | (170.42M) | (133.39M) | 842M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.